Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Skin Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 47Radiotherapy 37Fluorouracil 23Cetuximab 17pembrolizumab 11Carboplatin 11Paclitaxel 8Docetaxel 8Radiotherapy, Intensity-Modulated 6Chemotherapy, Adjuvant 6Surgical Procedures, Operative 5Standard of Care 5nimotuzumab 4Methotrexate 4Gabapentin 4Drug Therapy 4Afatinib 4Radiotherapy, Conformal 3Radiation 3Porfiromycin 3Nivolumab 3Neoadjuvant Therapy 3Fibroblast Growth Factor 7 3Bleomycin 3zalutumumab 2sargramostim 2epacadostat 2Tranexamic Acid 2Tirapazamine 2Pilocarpine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Head and Neck Neoplasms × linrodostat × Clear all
NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

Phase 3 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡